Illuminating somatostatin analog action at neuroendocrine tumor receptors
- 1 December 2013
- journal article
- review article
- Published by Elsevier in Trends in Pharmacological Sciences
- Vol. 34 (12) , 676-688
Abstract
No abstract availableKeywords
This publication has 160 references indexed in Scilit:
- Modification of ghrelin receptor signaling by somatostatin receptor-5 regulates insulin releaseProceedings of the National Academy of Sciences, 2012
- Phosphorylation of sst2 Receptors in Neuroendocrine Tumors after Octreotide Treatment of PatientsThe American Journal of Pathology, 2012
- GPCR mediated regulation of synaptic transmissionProgress in Neurobiology, 2012
- Adenosine A2A and A2B receptor expression in neuroendocrine tumours: potential targets for therapyPurinergic Signalling, 2011
- Differential G-protein-coupled Receptor Phosphorylation Provides Evidence for a Signaling Bar CodeJournal of Biological Chemistry, 2011
- Pituitary somatostatin receptor signalingTrends in Endocrinology & Metabolism, 2010
- Differential cytotoxicity of novel somatostatin and dopamine chimeric compounds on bronchopulmonary and small intestinal neuroendocrine tumor cell linesCancer, 2008
- Design and in Vitro Characterization of Highly sst2-Selective Somatostatin Antagonists Suitable for RadiotargetingJournal of Medicinal Chemistry, 2008
- Selective agonism in somatostatin receptor signaling and regulationMolecular and Cellular Endocrinology, 2008
- Radiolabeled somatostatin receptor antagonists are preferable to agonists forin vivopeptide receptor targeting of tumorsProceedings of the National Academy of Sciences, 2006